From fed batch to continuous: How perfusion enables smarter biologics production
From fed-batch to continuous processes, upstream strategies are evolving to enable smarter, more flexible biologics manufacturing.
In our latest whitepaper, Seohyeon Song, Lead Scientist and Associate Director of MSAT Upstream Processing at Samsung Biologics, explores how perfusion can be applied selectively as an upstream intensification option, complementing fed-batch manufacturing while enabling greater process flexibility.
Selective perfusion – upstream intensification strategy leveraging Samsung Biologics’ MSAT framework and fed‑batch expertise.
N‑1 perfusion – low‑risk, rapid productivity boost without moving to full‑continuous operation.
ATF‑based platforms with structured MSAT – scalable, manufacturing‑ready perfusion solution for next‑generation upstream processes.
From fed-batch to continuous processes, upstream strategies are evolving to enable smarter, more flexible biologics manufacturing.
In our latest whitepaper, Seohyeon Song, Lead Scientist and Associate Director of MSAT Upstream Processing at Samsung Biologics, explores how perfusion can be applied selectively as an upstream intensification option, complementing fed-batch manufacturing while enabling greater process flexibility.
- Selective perfusion – upstream intensification strategy leveraging Samsung Biologics’ MSAT framework and fed‑batch expertise.
- N‑1 perfusion – low‑risk, rapid productivity boost without moving to full‑continuous operation.
- ATF‑based platforms with structured MSAT – scalable, manufacturing‑ready perfusion solution for next‑generation upstream processes.
Related Content